NCT01793675已完成不适用
Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 116
- 试验地点
- 8
- 主要终点
- survival rate
研究概览
简要总结
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.
the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 2 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression
- •without identical sibling donor
排除标准
- •Contraindication to HSCT
- •Pregnancy
- •Mental illness
结局指标
主要结局
survival rate
时间窗: participants will be followed for an expected average of one year
number of participants with survival at one year
次要结局
- incidence of non-relapse mortality(one year)
研究者
Xiaojun Huang
Prof.
Peking University People's Hospital
研究点 (8)
Loading locations...
相似试验
招募中
不适用
Haploidentical Peripheral Blood Stem Cell Transplantation for Acute LeukemiaAcute LeukemiaNCT03756675Peking University People's Hospital45
Unknown
不适用
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell TransplantationRelapse LeukemiaAllogeneic Stem Cell TransplantationImmune Evasion, TumorNCT03964922Central Hospital, Nancy, France104
Unknown
不适用
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaAcute LeukemiaNCT05335226Institute of Hematology & Blood Diseases Hospital, China116
已完成
不适用
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell TransplantationHematopoietic Cell TransplantationOncologyNCT04727827Wake Forest University Health Sciences110
进行中（未招募）
1 期
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.Hematopoietic Stem Cell TransplantationMultiple MyelomaNCT03225417Fundación Pública Andaluza para la gestión de la Investigación en Sevilla142